Invisible burden of COVID-19: enzyme replacement therapy disruptions

Creative Commons License

Kahraman A. B., Yıldız Y., Çıkı K., Akar H. T., Erdal İ., Dursun A., ...More

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, vol.34, no.5, pp.539-545, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1515/jpem-2021-0067
  • Journal Name: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.539-545
  • Keywords: COVID-19, disruptions, enzyme replacement therapy, lysosomal storage diseases, survey, FABRY DISEASE, PATIENT
  • Hacettepe University Affiliated: Yes

Abstract

Objectives: Lysosomal storage diseases (LSD) constitute an important group of metabolic diseases, consisting of approximately 60 disorders. In some types of lysosomal diseases, enzyme replacement therapy (ERT) is administered intravenously in weekly or biweekly doses. Unfortunately, scheduled ERT during COVID-19 was disrupted. We considered the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders.